ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic analysis reveals the molecular mechanisms of deoxynivalenol-induced injury in the jejunum of piglets.BMC genomics · 2026Article
- Study on the Mechanism ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Psoriasis is an inflammatory dermatological condition challenging to treat and prone to recurrence. The pathogenesis of psoriasis is closely associated with metabolic disorders, while therapies targeting the dysregulated metabolism in psoriasis remain limited. Therefore, exploring the pathogenesis of psoriasis and identifying potential metabolic therapeutic targets is imperative. In this study, potential biomarkers for clinically targeted metabolic therapies in patients with psoriasis are aimed to be identified. RNA-sequencing analysis is performed on metabolism-related genes to identify differentially expressed metabolism-related genes. Then, various bioinformatics analyses and comprehensive functional experiments are conducted to verify the roles of the identified genes. A key gene SLC16A10 is identified with significant diagnostic and therapeutic potential for psoriasis. SLC16A10 is likely involved in arachidonic acid metabolism in keratinocytes through regulating thyroid hormone homeostasis, contributing to the development of psoriasis. SLC16A10 represents a promising therapeutic target for guttate psoriasis and can improve the outcomes of existing immune-targeted therapeutic agents. Comprehensive in vitro and in vivo experiments confirm that SLC16A10 downregulation alleviates the severity of psoriasis and hyperinflammation. Moreover, SLC16A10 may induce one of the sequelae of psoriasis, namely post-inflammatory hypopigmentation, by inhibiting melanogenesis. These findings demonstrate the potential of SLC16A10 as a diagnostic biomarker and therapeutic target for psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.